{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:04:34Z","timestamp":1758845074891,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ygyno.2023.02.016","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:58:18Z","timestamp":1681822698000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer"],"prefix":"10.1016","volume":"173","author":[{"given":"Jocelyn","family":"Garcia-Sayre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne G.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denice D.","family":"Tsao-Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulette","family":"Mhawech-Fauceglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiange","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia A.","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie L.","family":"Brunette-Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huyen Q.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie A.","family":"Yessaian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan G.","family":"Groshen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Facio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Aldana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila I.","family":"Muderspach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agustin A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ygyno.2023.02.016_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"year":"2019","series-title":"SEER Cancer Statistics Review, 1975\u20132017, National Cancer Institute. Bethesda, MD. Based on November 2019 SEER Data Submission, Posted to the SEER web site, April 2020","key":"10.1016\/j.ygyno.2023.02.016_bb0010"},{"issue":"1","key":"10.1016\/j.ygyno.2023.02.016_bb0015","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2023.02.016_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajog.2015.07.022","article-title":"Changing paradigms in the systemic treatment of advanced cervical cancer","volume":"214","author":"Pfaendler","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2023.02.016_bb0025","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1985.3.8.1079","article-title":"Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a gynecologic oncology group study","volume":"3","author":"Bonomi","year":"1985","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.02.016_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1997.15.1.165","article-title":"Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a gynecologic oncology group study","volume":"15","author":"Omura","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2023.02.016_bb0035","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2023.02.016_bb0040","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study","volume":"23","author":"Long","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2023.02.016_bb0045","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.02.016_bb0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11912-005-0007-z","article-title":"Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer","volume":"7","author":"Tewari","year":"2005","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.ygyno.2023.02.016_bb0055","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.02.016_bb0060","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.annonc.2021.04.009","article-title":"VP4\u20132021: EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator\u2019s choice (IC) chemotherapy (chemo) in recurrent\/metastatic (R\/M) cervical carcinoma","author":"Tewari","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.02.016_bb0065","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in recurrent cervical Cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ygyno.2023.02.016_bb0070","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of Pembrolizumab in previously treated advanced cervical Cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2023.02.016_bb0075","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2023.02.016_bb0080","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ygyno.2022.03.004","article-title":"Practice changing cervical cancer clinical trials","volume":"165","author":"Pothuri","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.02.016_bb0085","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.02.016_bb0090","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2001.19.5.1275","article-title":"Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study","volume":"19","author":"Curtin","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.02.016_bb0095","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.1996.14.3.792","article-title":"Paclitaxel has moderate activity in squamous cervix cancer. A gynecologic oncology group study","volume":"14","author":"McGuire","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2023.02.016_bb0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00001813-199708000-00002","article-title":"An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix","volume":"8","author":"Kudelka","year":"1997","journal-title":"Anti-Cancer Drugs"},{"issue":"9","key":"10.1016\/j.ygyno.2023.02.016_bb0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/COC.0000000000000394","article-title":"Efficacy of modified dose-dense paclitaxel in recurrent cervical Cancer","volume":"41","author":"Machida","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2023.02.016_bb0110","doi-asserted-by":"crossref","first-page":"15882","DOI":"10.1016\/S0021-9258(18)98491-7","article-title":"Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data","volume":"266","author":"Bai","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.ygyno.2023.02.016_bb0115","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1158\/1078-0432.CCR-08-2429","article-title":"A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies","volume":"15","author":"Goel","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.ygyno.2023.02.016_bb0120","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ygyno.2023.02.016_bb0125","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9769","key":"10.1016\/j.ygyno.2023.02.016_bb0130","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"10028","key":"10.1016\/j.ygyno.2023.02.016_bb0135","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2023.02.016_bb0140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2012.11.024","article-title":"The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival","volume":"128","author":"Matsuo","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.02.016_bb0145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.ygyno.2023.02.016_bb0150","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2217\/fon-2016-0530","article-title":"Efficacy and safety of eribulin in taxane-refractory patients in the \u2018real world\u2019","volume":"13","author":"Lorusso","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2023.02.016_bb0155","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s40064-015-1322-y","article-title":"Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies","volume":"4","author":"O'Shaughnessy","year":"2015","journal-title":"Springerplus"},{"issue":"3","key":"10.1016\/j.ygyno.2023.02.016_bb0160","article-title":"Current perspectives on Taxanes: focus on their bioactivity, delivery and combination therapy","volume":"10","author":"\u0160kubn\u00edk","year":"2021","journal-title":"Plants (Basel)"},{"issue":"2","key":"10.1016\/j.ygyno.2023.02.016_bb0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ygyno.2003.10.045","article-title":"Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"92","author":"Muggia","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"Pt 20","key":"10.1016\/j.ygyno.2023.02.016_bb0170","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1242\/jcs.00754","article-title":"The Bcl-2-regulated apoptotic pathway","volume":"116","author":"Willis","year":"2003","journal-title":"J. Cell Sci."},{"issue":"7","key":"10.1016\/j.ygyno.2023.02.016_bb0175","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2-family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ygyno.2023.02.016_bb0180","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.3748\/wjg.v11.i23.3498","article-title":"Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells","volume":"11","author":"Zheng","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ygyno.2023.02.016_bb0185","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-015-1553-x","article-title":"Overexpression of class III \u03b2-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer","volume":"15","author":"Du","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2023.02.016_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071434","article-title":"An emerging role for tubulin isotypes in modulating Cancer biology and chemotherapy resistance","volume":"18","author":"Parker","year":"2017","journal-title":"Int. J. Mol. Sci."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:04:34Z","timestamp":1758773074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":38,"alternative-id":["S0090825823000938"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}